P

Inventor

LOEW ANDREAS

US65 patents
⚠️ This page may combine multiple inventors who share the name “LOEW ANDREAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

NOVARTIS AG

21 patents
US10221245B2Mar 5, 2019

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

NOVARTIS AG36 citations94
US10253086B2Apr 9, 2019

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

NOVARTIS AG37 citations93
US10287354B2May 14, 2019

Regulatable chimeric antigen receptor

NOVARTIS AG29 citations92
US9458214B2Oct 4, 2016

Dual function fibroblast growth factor 21 proteins

NOVARTIS AG15 citations90
US10927184B2Feb 23, 2021

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

NOVARTIS AG10 citations86
US11149076B2Oct 19, 2021

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

NOVARTIS AG9 citations84
US8883735B2Nov 11, 2014

Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs

NOVARTIS AG8 citations84
US10640569B2May 5, 2020

Human mesothelin chimeric antigen receptors and uses thereof

NOVARTIS AG15 citations83
US10308717B2Jun 4, 2019

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

NOVARTIS AG4 citations83
US10577417B2Mar 3, 2020

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

NOVARTIS AG10 citations82
US12344657B2Jul 1, 2025

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

NOVARTIS AG1 citations73
US11028177B2Jun 8, 2021

Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

NOVARTIS AG4 citations73
US11865167B2Jan 9, 2024

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

NOVARTIS AG2 citations72
US11542488B2Jan 3, 2023

Sortase synthesized chimeric antigen receptors

NOVARTIS AG2 citations71
US9173960B2Nov 3, 2015

Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs

NOVARTIS AG2 citations63
US12559562B2Feb 24, 2026

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

NOVARTIS AG0 citations62
US11591404B2Feb 28, 2023

Treatment of cancer using a CD123 chimeric antigen receptor

NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020

Treatment of cancer using a CD123 chimeric antigen receptor

NOVARTIS AG1 citations62
US11578130B2Feb 14, 2023

Regulatable chimeric antigen receptor

NOVARTIS AG1 citations61
US11999794B2Jun 4, 2024

Human mesothelin chimeric antigen receptors and uses thereof

NOVARTIS AG0 citations60
US11981731B2May 14, 2024

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

NOVARTIS AG0 citations60

MARENGO THERAPEUTICS INC

11 patents

THOMSON LICENSING

5 patents

BROGDON JENNIFER

3 patents

LOEW ANDREAS

3 patents

BOETTCHER BRIAN R

2 patents

PHILIPS CORP

1 patent

CONG FENG

1 patent

NUANCE COMMUNICATIONS INC

1 patent

KOENIG LARS

1 patent

BROADCAST TELEVISION SYST

1 patent

Showing the top 50 of 65 patents by PatentIndex Score.